Abstract: Provided are modular prime editing systems, comprising: i) a fusion protein comprising a Cas9 nickase protein linked to a nucleotide polymerase (NT) protein, ii) a prime editor template RNA (petRNA) comprising a primer binding site (PBS), a nucleotide polymerase template (NPT), and at least one MS2 hairpin, and iii) a single guide RNA (sgRNA).

Abstract: The present invention is related to the field of gene editing. In particular, the gene editing is directed toward single nucleotide base editing. For example, such single nucleotide base editing results in a conversion of a mutated base pair to a wild type base pair. The high accuracy and precision of the presently disclosed single nucleotide base gene editor is accomplished by a fusion protein including an NmeCas9 nuclease and an inlaid nucleotide deaminase protein domain. The Nme2Cas9 protospacer interacting domain may be replaced with an SmuCas9 protospacer interacting domain.

Abstract: The present disclosure relates to compositions and methods for modifying a gene sequence, and for systems for delivering such compositions. For example, the disclosure relates to modifying a gene sequence using a CRISPR-Cas9 or other nucleic acid editing system, and methods and delivery systems for achieving such gene modification, such as viral or non-viral delivery systems.

Abstract: A modular prime editing (sPE) system is disclosed with separate and independent Cas9 nickase and reverse transcriptase template. This sPE system results in precise and efficient genome editing in cells and in adult mouse liver which is advantageous over conventional fusion proteins. Additionally, a pegRNA can be separated into an sgRNA and a prime editor template RNA, designated as a petRNA. This flexible, and modular system, is an improvement in the art to obtain precise genome editing.

Abstract: Genomic insertions, duplications, and insertion/deletion (indels) account for ˜14% of human pathogenic mutations. Current gene editing methods cannot accurately or efficiently correct these abnormal genomic rearrangements, especially larger alterations (>100 bp). The presently disclosed compositions and methods accurately delete insertions/duplications and repair the deletion junction to improve the scope of gene therapies. For example, a Cas9 prime editor (PECas9) is combined with two prime editing guide RNAs (pegRNAs) targeting complementary DNA strands. PECas9 can replace an ˜1-kb genomic fragment with a desired sequence at the target site without requiring an exogenous DNA template.

Abstract: The present applications discloses an NLS-optimized SpCas9-based prime editor that improves genome editing efficiency exemplified by endogenous loci in cultured cell lines. Using this genome modification system, tumor formation can be initiated through somatic cell editing in the adult mouse. Furthermore, a dual adeno-associated vims (AAVs) is utilized for the delivery of a split-intein prime editor for correction of in vivo pathogenic mutations.

Abstract: An automated microfluidic bioreactor device and methods to rapidly detect drugs of abuse from human sweat are provided. The bioreactor can perform either single-plexed measurements (detecting only one target analyte at a time) or multiplexed measurement (detecting multiple analytes simultaneously). The bioreactor device has a cartridge comprising a capillary array that employs competitive enzyme-linked immunosorbent assay (ELISA) to detect the presence of various drugs or metabolite compounds. For example, four common drugs, methadone, methamphetamine, amphetamine, and tetrahydrocannabinol, were detected rapidly and quantitatively in about 16 minutes with a low sweat sample volume (about 4 ?L per analyte) and a large dynamic range (methadone: 0.0016 ng/mL-1 ng/mL; METH: 0.016 ng/mL-25 ng/mL; amphetamine: 0.005 ng/mL-10 ng/mL; THC: 0.02 ng/mL-1000 ng/mL).

Abstract: The present invention is related to compositions and methods for gene therapy. Several approaches described herein utilize the Neisseria meningitidis Cas9 system that provides a hyperaccurate CRISPR gene editing platform. Furthermore, the invention incorporates full length and truncated single guide RNA sequences that permit a complete sgRNA-Nme1Cas9 vector to be inserted into an adeno-associated viral plasmid that is compatible for in vivo administration. Furthermore, Type II-C Cas9 orthologs have been identified that target protospacer adjacent motif sequences limited to between one-four required nucleotides.

Abstract: A hand-held photographing device capable of outputting panoramic images includes a screen, a plurality of camera modules, and a control device. The screen is curved and extends to cover multiple surfaces of the device. The camera modules are located on different surfaces of the device, and the camera modules which are on the same surfaces of the panoramic photographing device as the screen are covered by the screen. Each camera module includes a large wide-angle camera. The control device issues instructions to the camera modules. Images from different directions are collected and the multiple images are used to synthesize a panoramic image for storage or display. The present disclosure also provides a panoramic image photographing method, which is applied to a panoramic photographing device.

Abstract: The present disclosure relates to compositions and methods for modifying a gene sequence, and for systems for deliverying such compositions. For example, the disclosure relates to modifying a gene sequence using a CRISPR-Cas9 or other nucleic acid editing system, and methods and delivery systems for achieving such gene modification, such as viral or non-viral delivery systems.

Abstract: The present disclosure relates to compositions and methods for modifying a gene sequence, and for systems for delivering such compositions. For example, the disclosure relates to modifying a gene sequence using a CRISPR-Cas9 or other nucleic acid editing system, and methods and delivery systems for achieving such gene modification, such as viral or non-viral delivery systems.

Abstract: The invention relates to methods of altering resistance to lodging in maize, transgenic plants with altered resistance to lodging and methods for making such plants. In particular, the invention comprises altering the expression or levels of at least one laccase gene and/or altering the expression or activity of miR528.

Abstract: Ways of allocating an identifier to a mobile device are disclosed. One method includes receiving a request that requests an address be assigned to the mobile device, considering factors in connection with determining a mobile IP (MIP) address to be assigned to the mobile device, determining the MIP address based on the factors, and conveying the MIP address to the mobile device.

Abstract: The present invention is related to compositions and methods for gene therapy. Several approaches described herein utilize the Neisseria meningitidis Cas9 system that provides a hyperaccurate CRISPR gene editing platform. Furthermore, the invention incorporates full length and truncated single guide RNA sequences that permit a complete sgRNA-Nme1Cas9 vector to be inserted into an adeno-associated viral plasmid that is compatible for in vivo administration. Furthermore, Type II-C Cas9 orthologs have been identified that target protospacer adjacent motif sequences limited to between one-four required nucleotides.

Abstract: The disclosure relates to compositions comprising and methods for chemical modification of single guide RNA (sgRNA), tracrRNA and/or crRNA used individually or in combination with one another or Cas system components. Compositions comprising modified ribonucleic acids have been designed with chemical modification for even higher efficiency as unmodified native strand of sgRNA. Administration of modified ribonucleic acids will allow decreased immune response when administered to a subject, increased stability, increased editing efficiency and facilitated in vivo delivery of sgRNA via various delivery platforms. The disclosure also relates to methods of decreasing off-target effect of CRISPR and a CRISPR complex.

Abstract: The present disclosure relates to compositions and methods for modifying a gene sequence, and for systems for delivering such compositions. For example, the disclosure relates to modifying a gene sequence using a CRISPR-Cas9 or other nucleic acid editing system, and methods and delivery systems for achieving such gene modification, such as viral or non-viral delivery systems.

Abstract: The present disclosure relates to compositions and methods for modifying a gene sequence, and for systems for delivering such compositions. For example, the disclosure relates to modifying a gene sequence using a CRISPR-Cas9 or other nucleic acid editing system, and methods and delivery systems for achieving such gene modification, such as viral or non-viral delivery systems.

Abstract: The present disclosure relates to compositions and methods for modifying a gene sequence, and for systems for delivering such compositions. For example, the disclosure relates to modifying a gene sequence using a CRISPR-Cas9 or other nucleic acid editing system, and methods and delivery systems for achieving such gene modification, such as viral or non-viral delivery systems.

Abstract: Methods and systems for selective scanning and connecting to a wireless network are described. In an example, a mobile device may be configured to scan for availability of a wireless network and measure, at the mobile device, signal strengths of a wireless signal from the wireless network. Also, the mobile device may be configured to determine a rate of signal strength change for the wireless signal from the wireless network based on the measured signal strengths; and compare the rate of signal strength change to a threshold value. If the rate of signal strength change is less than the threshold value, the mobile device may be configured to establish a connection with the wireless network; if not, the mobile device may be configured to stop scanning for the wireless network.

Abstract: In a packet communication system, session border controllers receive and process communication packets to detect DTMF signaling. If DTMF signaling is detected, the session border controllers determine if DTMF transcoding is required. If DTMF transcoding is required, the session border controllers transfer DTMF transcoding instructions to a DTMF transcoding server. In response to the transcoding instructions, the DTMF transcoding server transfers transcoded DTMF signaling.